Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 18/20 | 0.79 |
| ▸ | KDM6B | O15054 | 1/20 | 0.68 |
| ▸ | KDM6A | O15550 | 1/20 | 0.68 |
| ▸ | TOP2A | P11388 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378442 | 0.88 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6A | |
| SCHEMBL1377482 | 0.88 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6ATOP2A | |
| SCHEMBL13866531 | 0.87 | ESR1 (0.62) | ESR1ESR2KDM6BKDM6ATOP2A | |
| SCHEMBL1377423 | 0.87 | ESR1 (0.78) | ESR1ESR2KDM6BKDM6A | |
| SCHEMBL13866517 | 0.86 | TOP2A (0.62) | ESR1ESR2KDM6BKDM6ATOP2A | |
| SCHEMBL3932428 | 0.86 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6ATOP2A | |
| SCHEMBL1550348 | 0.85 | TOP2A (0.79) | ESR1ESR2KDM6BKDM6ATOP2A | |
| SCHEMBL13866514 | 0.85 | TOP2A (0.60) | ESR1ESR2KDM6BKDM6ATOP2A | |
| SCHEMBL9197515 | 0.84 | ESR1 (0.68) | ESR1ESR2KDM6BKDM6A | |
| SCHEMBL802768 | 0.84 | HSD17B10 (0.60) | ESR1ESR2KDM6BKDM6ATOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350032-B1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2350032-B1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| EP-2350032-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| WO-2010036905-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036908-A1 | USE OF BENZOXAZOLE COMPOUNDS IN THE TREATMENT OF MALARIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036905-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | CYP4X1, CYP3A5, CYP3A7 | ESR1 2407/4885ESR2 2935/4885KDM6B 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.